Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET
Company Participants
Jennifer Good – President and Chief Executive Officer
Lisa Delfini – Chief Financial Officer
Conference Call Participants
Serge Belanger – Needham & Company
Sean Kim – Jones Trading
Annabel Samimy – Stifel
Operator
Good afternoon and welcome to the Trevi Therapeutics’ Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Various remarks that management makes during this conference call about the company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company’s most recent annual report on Form 10-K which the company filed with the SEC this afternoon. In addition, any forward-looking statement represent the company’s views only as of today and should not be relied upon as representing the company’s views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so even if its views change.
I would now like to turn the conference call over to Jennifer Good, Trevi’s President and CEO. Please go ahead.
Jennifer Good
Good afternoon. And thank you for joining our first quarter earnings call and business update.
Joining me today on this call is Lisa Delfini, Trevi’s Chief Financial Officer. Lisa and I have some prepared remarks, then we will open it up for questions.
During the first quarter, we continued to advance our clinical development plans for Haduvio for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis or IPF, other chronic cough indications and prurigo nodularis.
Let me provide an update on each of our programs. Beginning with our lead program in chronic cough and IPF. IPF is a serious, end-of-life disease and chronic cough is a major cause of morbidity that significantly impacts a patient’s quality of life. There are no approved therapies for the treatment of chronic cough and IPF and the cough is often refractory to anti tested therapy. Patients with chronic cough and IPF can cough up to 1500 times per day leading to fatigue, air hunger and increased anxiety. The chronic cough in IPF is also hypothesized to potentially enhance activation of pro fibrotic mechanisms and disease worsening. We are planning to conduct two studies in parallel during this next phase of development in our IPF chronic cough program.